RSS0393 / Jiangsu Hengrui Pharma - LARVOL DELTA

A Randomized, Double-blind, Vehicle-controlled Phase I Study Evaluating the Safety and Pharmacokinetic Profile of RSS0393 Ointment as a Single and Multiple Dose Ascending Local Dermal Administration in Healthy and Adult Subjects with Psoriasis (EADV 2025) - P1 | "Local dermal administration of RSS0393 showed acceptable safety and tolerance of in healthy subjects and potential efficacy in psoriasis patients. These results support further clinical development of RSS0393 ointment for plaque psoriasis."

Clinical • P1 data • PK/PD data • Dermatology • Immunology • Psoriasis

A Phase II Trial of the Safety and Efficacy of RSS0309 Ointment in Adults With Atopic Dermatitis (clinicaltrials.gov) - P2 | N=168 | Recruiting | Sponsor: Reistone Biopharma Company Limited | Not yet recruiting ➔ Recruiting

Enrollment open • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

A Phase II Trial of the Safety and Efficacy of RSS0309 Ointment in Adults With Atopic Dermatitis (clinicaltrials.gov) - P2 | N=168 | Not yet recruiting | Sponsor: Reistone Biopharma Company Limited

New P2 trial • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

A Clinical Study to Evaluate the Safety and Pharmacokinetics of Topical RSS0393 Ointment in Children and Adolescents With Plaque Psoriasis (clinicaltrials.gov) - P2 | N=20 | Not yet recruiting | Sponsor: Jiangsu HengRui Medicine Co., Ltd.

New P2 trial • Dermatology • Immunology • Psoriasis

Randomized, Double-blind, Placebo-controlled Study of RSS0393 Ointment in Healthy and Psoriatic Subjects (clinicaltrials.gov) - P1 | N=98 | Active, not recruiting | Sponsor: Jiangsu HengRui Medicine Co., Ltd. | Not yet recruiting ➔ Active, not recruiting | Trial completion date: Oct 2024 ➔ Dec 2025 | Trial primary completion date: Aug 2024 ➔ Dec 2025

Enrollment closed • Trial completion date • Trial primary completion date • Dermatology • Immunology • Psoriasis

To Evaluate the Efficacy and Safety of RSS0393 Ointment in Patients With Plaque Psoriasis Phase II Study (clinicaltrials.gov) - P2 | N=147 | Not yet recruiting | Sponsor: Jiangsu HengRui Medicine Co., Ltd.

New P2 trial • Dermatology • Immunology • Psoriasis

Randomized, Double-blind, Placebo-controlled Study of RSS0393 Ointment in Healthy and Psoriatic Subjects (clinicaltrials.gov) - P1 | N=88 | Not yet recruiting | Sponsor: Jiangsu HengRui Medicine Co., Ltd.

New P1 trial • Dermatology • Immunology • Psoriasis